APO Research
Talk to an analyst

APO RESEARCH · REPORT

23-Valent Pneumococcal Polysaccharide Vaccine

23-Valent Pneumococcal Polysaccharide Vaccine is a vaccine product category defined by its pneumococcal antigen composition and formulation.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

The commercial boundary

The selected edition describes a market scope. Product approvals, labelled use and clinical acceptance require their own evidence; neither report segmentation nor an illustrative image establishes medical suitability.

Which antigen composition and formulation define the vaccine?

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

Selected research

Market Structure

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026172 pages

Choose your research edition.

Industry Research23-Valent Pneumococcal Polysaccharide Vaccine Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

The major players in global 23-Valent Pneumococcal Polysaccharide Vaccine market include MSD, Sanofipasteur, etc. The top 2 players occupy about 80% shares of the global market. North America and Europe are main markets, they occupy about 50% of the global market. Single Dose Vial is the main type, with a share about 60%. For Children (2-10) is the main application, which holds a share about 40%.

Read the full market overview

This report provides an overview of the global 23-Valent Pneumococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of 23-Valent Pneumococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents 23-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 23-Valent Pneumococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Company

MSD

Sanofipasteur

CDIBP

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type

Single Dose Vial

Pre-filled Syringe

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application

For Children (2-10)

For Person (10-64)

For The Old (Above or equal to 65)

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 23-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 23-Valent Pneumococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the 23-Valent Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends Table 2. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers Table 3. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints Table 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers (K Dose) & (2021-2026) Table 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers Table 9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers, Product Type & Application Table 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Single Dose Vial Table 17. Major Manufacturers of Pre-filled Syringe Table 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Dose) Table 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Dose) Table 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (K Dose) Table 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (K Dose) Table 26. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of For Children (2-10) Table 29. Major Manufacturers of For Person (10-64) Table 30. Major Manufacturers of For The Old (Above or equal to 65) Table 31. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Dose) Table 32. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 33. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 34. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 35. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 36. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Dose) Table 37. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (K Dose) Table 38. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (K Dose) Table 39. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Table 42. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Dose) Table 43. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 44. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Forecasted by Region (2027-2032) & (K Dose) Table 45. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 47. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 48. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 49. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 50. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 51. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 52. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 53. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 54. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 55. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 56. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 57. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 58. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 63. MSD Company Information Table 64. MSD Business Overview Table 65. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 67. MSD Recent Development Table 68. Sanofipasteur Company Information Table 69. Sanofipasteur Business Overview Table 70. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 72. Sanofipasteur Recent Development Table 73. CDIBP Company Information Table 74. CDIBP Business Overview Table 75. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 77. CDIBP Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. 23-Valent Pneumococcal Polysaccharide Vaccine Distributors List Table 81. 23-Valent Pneumococcal Polysaccharide Vaccine Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. 23-Valent Pneumococcal Polysaccharide Vaccine Product Image Figure 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (2021-2032) & (K Dose) Figure 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (US$/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Single Dose Vial Image Figure 9. Pre-filled Syringe Image Figure 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 16. For Children (2-10) Image Figure 17. For Person (10-64) Image Figure 18. For The Old (Above or equal to 65) Image Figure 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 26. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 28. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 29. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 30. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 31. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 33. France 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 34. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 35. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 36. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 37. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 38. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 39. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 40. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 41. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 42. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 43. India 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 44. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 45. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 46. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 48. South Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 49. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 50. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 51. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 52. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 53. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 54. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (K Dose) Figure 55. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Single Dose Vial
  • Pre-filled Syringe
Applications
  • For Children (2-10)
  • For Person (10-64)
  • For The Old (Above or equal to 65)
Companies covered
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
3 23-Valent Pneumococcal Polysaccharide Vaccine Market by Manufacturers
  1. 3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 23-Valent Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
4 23-Valent Pneumococcal Polysaccharide Vaccine Market by Type
  1. 4.1 23-Valent Pneumococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Single Dose Vial
  3. 4.1.2 Pre-filled Syringe
  4. 4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type
  5. 4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type
  9. 4.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
5 23-Valent Pneumococcal Polysaccharide Vaccine Market by Application
  1. 5.1 23-Valent Pneumococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 For Children (2-10)
  3. 5.1.2 For Person (10-64)
  4. 5.1.3 For The Old (Above or equal to 65)
  5. 5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application
  6. 5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application
  10. 5.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region
  1. 6.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region
  1. 7.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region
  2. 7.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032)
  8. 7.2.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 MSD
  2. 8.1.1 MSD Company Information
  3. 8.1.2 MSD Business Overview
  4. 8.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 MSD Recent Developments
  7. 8.2 Sanofipasteur
  8. 8.2.1 Sanofipasteur Company Information
  9. 8.2.2 Sanofipasteur Business Overview
  10. 8.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Sanofipasteur Recent Developments
  13. 8.3 CDIBP
  14. 8.3.1 CDIBP Company Information
  15. 8.3.2 CDIBP Business Overview
  16. 8.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 CDIBP Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process
  6. 9.2 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 23-Valent Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst